Montefiore Einstein Cancer Center Finds CAR-T Therapy Effective in Black and Hispanic Patients

In a study published April 28 in Bone Marrow Transplantation (BMT), investigators at the National Cancer Institute-designated Montefiore Einstein Cancer Center (MECC) report that Black and Hispanic patients had outcomes and side effects following CAR-T treatment that were comparable to their white and Asian counterparts.

“Representation in cancer clinical trials is vital to ensuring that treatments are safe and effective for everyone,” said Mendel Goldfinger, MD, co-corresponding author of the paper, a medical oncologist at Montefiore Health System, Assistant Professor of Medicine at Albert Einstein College of Medicine, and member of the MECC Cancer Therapeutics Program. “We couldn’t have been happier to learn that our patients who identify as Black and Hispanic have the same benefits from CAR-T therapy as white patients. We can only begin to say that a cancer treatment is transformational when these therapies benefit everyone who comes to us for care.”

People who identify as Black and Hispanic often have tumor biology, immune system biology and side effects that are distinct from those of white people. However, very few minorities were enrolled in the major trials that led the FDA to approve CAR-T cell therapy.

The new BMT study evaluated outcomes for 46 participants treated at Montefiore between 2015 and 2021. Seventeen of the participants were Hispanic, 9 were African American, 15 were white and 5 were Asian.

Among Black and Hispanic patients, 58% achieved a complete response after treatment and 19% achieved a partial response. For white and Asian patients, 70% achieved a complete response and 20% had a partial response, indicating no statistical differences among racial and ethnic backgrounds. Results were similar with respect to major side effects experienced: Approximately 95% of participants in each group had mild to moderate cytokine release syndrome, a common side effect to immunotherapy in which people experience fever and other flu-like symptoms.

“Our findings demonstrate that we are able to effectively treat people from historically marginalized groups using CAR-T; our hope is that more people from a diverse range of racial and ethnic backgrounds will be included in clinical trials,” said co-author Amit Verma, MBBS, Associate Director of Translational Science at MECC, Director of the Division of Hemato-Oncology at Montefiore Einstein, and Professor of Medicine and of Developmental and Molecular Biology at Einstein. Ira Braunschweig, MD, Associate Professor of Medicine at Einstein, Director of Stem Cell Transplantation and Cellular Therapy, and Clinical Program Director, Hematologic Malignancies at Montefiore, was also co-corresponding author of the study.

At Montefiore, approximately 80% of clinical trial participants are minorities, compared with the nationwide figure of only 8%.

“As an academic medical center, it is not enough to make novel therapies like CAR-T available,” said Susan Green-Lorenzen, RN, MSN, System Senior Vice President of Operations at Montefiore Health System and study co-author. “We need to be at the forefront of ensuring that these treatments are effective for the communities we serve — this research reflects this commitment.”

The study is titled “Efficacy and safety of CAR-T cell therapy in minorities.” In addition to Drs. Goldfinger, Verma and Braunschweig and Ms. Susan Green-Lorenzen, other Montefiore Einstein authors are Astha Thakkar, MD; Michelly Abreu, NP; Kith Pradhan, PhD; R. Alejandro Sica, MD; Aditi Shastri, MD; Noah Kornblum, MD; Nishi Shah, MD, MPH; Ioannis Mantzaris, MD, MS; Kira Gritsman, MD, PhD; Eric Feldman, MD; and Richard Elkind, PA-C.